Privia Health Group, Inc. (PRVA) Key Metrics
PRVA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.88B
- Enterprise value
- $2.04B
- P/E (TTM)
- 107.2 10-yr median 133.3
- Forward P/E
- 17.3
- PEG ratio
- —
- Price / sales
- 1.2 10-yr median 1.7
- Price / book
- 3.1 10-yr median 5.0
- EV / EBITDA
- 35.8 10-yr median 56.1
- Dividend yield
- —
- Beta
- 0.80
PRVA key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPRVA valuation Price multiples at each fiscal year-end price.
PRVA returns How much profit the business earns on the capital it uses.
PRVA per-share figures Results divided by the shares outstanding at year-end.
PRVA financial health Debt, liquidity and how easily interest is covered.
PRVA efficiency & capital use Working capital cycle and where the cash goes.
PRVA valuation history
PRVA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRVA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRVA price vs earnings per share
PRVA key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $3.06B | $2.46B | $2.87B | $2.51B | $2.79B | — | — | — |
| Enterprise value | $2.59B | $1.97B | $2.49B | $2.18B | $2.52B | — | — | — |
| P/E ratio | 133.3 | 170.7 | 124.4 | — | — | — | — | — |
| Price / sales | 1.4 | 1.4 | 1.7 | 1.9 | 2.9 | — | — | — |
| Price / book | 4.1 | 3.9 | 5.1 | 5.0 | 6.5 | — | — | — |
| Price / free cash flow | 18.8 | 23.6 | 35.6 | 53.4 | 51.2 | — | — | — |
| Price / operating cash flow | 18.7 | 22.5 | 35.5 | 53.3 | 50.7 | — | — | — |
| EV / sales | 1.2 | 1.1 | 1.5 | 1.6 | 2.6 | — | — | — |
| EV / EBITDA | 48.0 | 56.1 | 70.0 | — | — | — | — | — |
| EV / free cash flow | 15.9 | 18.9 | 30.9 | 46.2 | 46.2 | — | — | — |
| Earnings yield | 0.7% | 0.6% | 0.8% | −0.3% | −6.7% | — | — | — |
| Free cash flow yield | 5.3% | 4.2% | 2.8% | 1.9% | 2.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $23.71 | $19.55 | $23.03 | $22.71 | $25.87 | — | — | — |
| Per share | ||||||||
| Revenue per share | $16.47 | $13.82 | $13.30 | $12.26 | $8.96 | $7.73 | $7.44 | $6.40 |
| Earnings per share | $0.18 | $0.11 | $0.19 | −$0.08 | −$1.75 | $0.30 | $0.08 | −$0.03 |
| Operating cash flow per share | $1.27 | $0.87 | $0.65 | $0.43 | $0.51 | $0.37 | $0.23 | $0.05 |
| Free cash flow per share | $1.26 | $0.83 | $0.65 | $0.43 | $0.51 | $0.36 | $0.18 | $0.05 |
| Cash per share | $3.72 | $3.91 | $3.12 | $3.14 | $2.97 | $0.80 | $0.44 | $0.38 |
| Book value per share | $5.72 | $5.06 | $4.50 | $4.51 | $3.96 | $1.39 | $1.04 | $0.86 |
| Tangible book value per share | $2.42 | $3.06 | $2.53 | $2.84 | $2.22 | $0.21 | −$0.14 | −$0.36 |
| Capex per share | $0.01 | $0.04 | $0.00 | $0.00 | $0.01 | $0.00 | $0.05 | $0.00 |
| Debt per share | $0.07 | $0.04 | $0.07 | $0.10 | $0.43 | $0.32 | $0.41 | $0.65 |
| Shares outstanding | 128.9M | 125.6M | 124.7M | 110.7M | 107.8M | 105.7M | 105.7M | 102.8M |
| Change in shares outstanding | +2.6% | +0.7% | +12.6% | +2.6% | +2.0% | 0.0% | +2.8% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 3.3% | 2.4% | 4.4% | −1.9% | −65.6% | 24.3% | 8.3% | −3.4% |
| Return on invested capital (ROIC) | 11.1% | 6.3% | 8.7% | −9.6% | −138.2% | 25.1% | 12.5% | 1.5% |
| Return on assets (ROA) | 1.8% | 1.3% | 2.6% | −1.2% | −37.1% | 10.4% | 3.2% | −1.2% |
| Return on tangible assets | 2.4% | 1.6% | 3.1% | −1.4% | −37.7% | 15.3% | 5.7% | −2.5% |
| Free cash flow margin | 7.6% | 6.0% | 4.9% | 3.5% | 5.6% | 4.7% | 2.4% | 0.8% |
| Income quality (OCF / net income) | 7.13 | 7.60 | 3.50 | — | — | 1.24 | 2.95 | — |
| Financial health | ||||||||
| Total debt | $9.5M | $5.6M | $8.3M | $11.5M | $46.5M | $33.7M | $43.1M | $67.0M |
| Cash & short-term investments | $479.7M | $491.1M | $389.5M | $348.0M | $320.6M | $84.6M | $46.9M | $39.1M |
| Net debt | −$470.2M | −$485.6M | −$381.2M | −$336.5M | −$274.1M | −$51.0M | −$3.8M | $27.9M |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.11 | 0.23 | 0.39 | 0.76 |
| Debt / assets | 0.01 | 0.00 | 0.01 | 0.01 | 0.07 | 0.10 | 0.16 | 0.27 |
| Net debt / EBITDA | −8.73 | −13.82 | −10.72 | — | — | −1.87 | −0.22 | 8.64 |
| Current ratio | 1.60 | 1.86 | 1.81 | 2.09 | 2.35 | 1.29 | 1.12 | 1.14 |
| Quick ratio | 1.60 | 1.86 | 1.81 | 2.09 | 2.35 | 1.29 | 1.12 | 1.14 |
| Interest coverage | — | — | 2.5 | -35.3 | -203.2 | 13.2 | 2.3 | 0.3 |
| Working capital | $342.5M | $385.7M | $313.9M | $287.7M | $256.2M | $43.1M | $14.4M | $14.2M |
| Invested capital | $267.1M | $149.6M | $180.2M | $162.6M | $152.8M | $95.8M | $106.4M | $116.4M |
| Tangible asset value | $365.2M | $432.0M | $361.0M | $334.7M | $262.5M | $19.0M | −$17.8M | −$39.9M |
| Net current asset value | $332.6M | $382.5M | $308.3M | $278.2M | $210.5M | $4.8M | −$33.1M | −$48.0M |
| Graham number | $4.78 | $3.61 | $4.33 | — | — | $3.04 | $1.35 | — |
| Graham net-net per share | $1.57 | $2.20 | $1.72 | $1.96 | $1.60 | −$0.25 | −$0.55 | −$0.69 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | 0.0% | 0.0% | — | — | — |
| Capex / revenue | 0.1% | 0.3% | 0.0% | 0.0% | 0.1% | 0.0% | 0.7% | 0.0% |
| Capex / operating cash flow | 0.7% | 4.6% | 0.1% | 0.2% | 1.0% | 1.0% | 23.4% | 4.2% |
| Capex / depreciation | 0.12 | 0.69 | 0.02 | 0.02 | 0.22 | 0.21 | 4.00 | 0.21 |
| Stock-based compensation / revenue | 3,347.8% | 3.3% | 2.2% | 5.0% | 26.2% | 0.1% | 0.0% | 0.3% |
| SG&A / revenue | 7.8% | 8.8% | 8.1% | 11.0% | 28.8% | 6.8% | 6.5% | 8.1% |
| Efficiency | ||||||||
| Days sales outstanding | 61.6 | 63.8 | 52.9 | 41.3 | 40.9 | 39.4 | 34.5 | 39.5 |
| Days of inventory on hand | — | — | 0.0 | 0.0 | 0.0 | — | 0.0 | — |
| Days payables outstanding | 1.7 | 2.1 | 1.8 | 1.4 | 1.7 | 1.4 | 1.3 | 2.8 |
| Cash conversion cycle (days) | 60.0 | 61.7 | 51.1 | 39.8 | 39.2 | 38.0 | 33.1 | 36.7 |
| Receivables turnover | 5.92 | 5.72 | 6.90 | 8.84 | 8.92 | 9.26 | 10.59 | 9.24 |
| Payables turnover | 215.86 | 176.85 | 204.78 | 251.83 | 219.92 | 255.03 | 276.64 | 128.86 |
| Inventory turnover | — | — | 1,496,236,000.00 | 1,221,878,000.00 | 902,558,000.00 | — | 717,888,000.00 | — |
| Asset turnover | 1.69 | 1.63 | 1.85 | 1.83 | 1.90 | 2.73 | 3.03 | 2.64 |
| Average receivables | $358.5M | $303.5M | $240.2M | $153.5M | $108.3M | $88.2M | $74.2M | $71.2M |
| Average payables | $8.9M | $8.8M | $7.3M | $4.9M | $4.1M | $2.9M | $2.6M | $4.7M |
| Average inventory | — | — | $1 | $1 | $1 | — | $1 | — |
| Intangibles / total assets | 31.1% | 22.1% | 24.6% | 23.2% | 27.3% | 37.9% | 46.4% | 50.5% |
Computed from PRVA's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PRVA valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Privia Health traded at 133.3 times earnings, against a 8-year median of 133.3. Based on the latest twelve months, the trailing P/E is 107.2 and the forward P/E is 17.3. Privia Health earned a return on equity of 3.3% and a return on invested capital of 11.1% in fiscal 2025. It ended the year with $9.5 million of debt and $479.7 million in cash and short-term investments, a net cash position of $470.2 million. The share count rose 25.4% from 102.8M to 128.9M over 7 years.
See the PRVA income statement, the PRVA chart for price history, or the PRVA stock overview for the latest quote and news.
PRVA key metrics FAQ
What is Privia Health's P/E ratio?
Privia Health's trailing P/E ratio is 107.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 17.3. At the end of fiscal 2025 it was 133.3, compared with a 8-year median of 133.3.
What is Privia Health's EV/EBITDA?
Privia Health's enterprise value was 48.0 times EBITDA at the end of fiscal 2025 (enterprise value $2.6 billion, EBITDA $53.8 million); the current EV/EBITDA is 35.8.
What is Privia Health's return on equity?
Privia Health's return on equity (ROE) was 3.3% in fiscal 2025: net income of $22.9 million on average shareholders' equity of $686.2 million.
What is Privia Health's ROIC?
Privia Health's return on invested capital was 11.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Privia Health have?
Privia Health had total debt of $9.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Privia Health's free cash flow yield?
Privia Health generated $162.2 million of free cash flow in fiscal 2025, a free cash flow yield of 5.3% on its market value at year-end ($3.1 billion).
What is Privia Health's current ratio?
Privia Health's current ratio was 1.60 at the end of fiscal 2025: current assets were 1.60 times current liabilities.